To account for the ViroPharma and Intrexon arrangements, we identified the deliverables included within each arrangement and determined if there were separate units of accounting as defined in ASC 605-25.
ASC 605-25-25-4 states a vendor should evaluate all the deliverables in an arrangement to determine whether they can be separated into multiple units of accounting. That evaluation should be performed at the inception of the arrangement and as each item in the arrangement is delivered.
Rest of the answer
ASC 605-25-25-5 states in an arrangement with multiple deliverables, the delivered item or items shall be considered a separate unit of accounting if both of the following criteria are met:
1)
The delivered item or items have value to the customer on a standalone basis,
2)
If the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item or items is considered probable and substantially in the control of the vendor.
If both of the separation criteria are met, separation of the deliverables is not optional. The deliverables in an arrangement that meet the separation criteria above must be accounted for as separate units of accounting for revenue recognition purposes. If either of the separation criteria is not met for a delivered item in a multiple-element arrangement, the delivered item is accounted for as a combined unit of accounting with the undelivered item(s).
The
ViroPharma and Intrexon arrangements have identical deliverables; therefore, we will address them together. At the inception of the ViroPharma and Intrexon arrangements, we identified three deliverables which are (1) the license to our proprietary enzyme, the recombinant human hyalurondiase (rHuPH20), (2) research and development (R&D) services and (3) supply of rHuPH20 active pharmaceutical ingredient (API). We determined that the license, R&D services and rHuPH20 API supply individually represent separate units of accounting, because each deliverable has standalone value.
The first criterion that must be met to separately account for deliverables in a multiple-element arrangement is that the delivered item or items have value to the customer on a standalone basis. ASC 605-25-25-5(a) states that a delivered item has standalone value to the customer when either:
Any vendor can sell that item separately, or
The customer could resell that item on a standalone basis. In the context of a customer’s ability to resell the delivered item(s), this criterion does not require the existence of an observable market for the deliverable(s).
The second criteria that must be met to separately account for deliverables in a multiple-element arrangement is that in situations in which a general right of return exists for the delivered item, delivery or performance of the undelivered items(s) is considered probable and is substantially within the control of the company. There is no general right of return within the ViroPharma and Intrexon collaboration agreements and therefore this criterion was not considered further.
License Standalone Value determined that the delivered license has standalone value because upon the receipt of the license, ViroPharma and Intrexon are able to use the license for its intended purpose without the receipt of the remaining deliverables. We believe that
ViroPharma and Intrexon each has internal product development capabilities and/or can utilize expertise and resources from other vendors to develop and move their respective programs forward without our R&D services. We also believe that
ViroPharma and Intrexon can acquire rHuPH20 API supply from other vendors to further develop and move their respective programs forward without the supply of rHuPH20 API from us.
In a December 7, 2009 SEC Staff speech by Arie Wildenburg, the Staff illustrated in an example that it would be possible to demonstrate standalone value, despite not selling the item separately or the customer not having the ability to resell the item on a standalone basis. The Staff also concluded that the analysis of standalone value should be based on the individual facts and circumstances of each arrangement. Below is an excerpt from that speech (emphasis added).
“Consider an arrangement that contains the following two deliverables:
1. Delivered Item: Biotech License of Technology
2. Undelivered Item: Proprietary Research and Development Services
In this example, assume the Biotech owns certain technology that will be used in the development of a new drug, and since we’re being creative; let’s imagine it’s a drug that can cure hair loss without any side effects. This technology is unique, such that no other vendor sells a similar item. Also, assume the Biotech will never sell this technology on its own;
rather it will always be sold with the R&D services, which are essential in order to derive value from the technology. Finally, as a protective measure, the Biotech has included a contractual restriction that prevents the customer from sub-licensing or reselling the technology.
Given this set of facts, the license does not have stand-alone value. First, the technology is not sold separately by anyone. Second, the customer cannot resell the technology. Therefore, the license should be combined with the R&D services as a single unit of accounting.
However, there may be a number of ways in which this fact pattern could be modified such that the license would have stand-alone value.
For example, what if the R&D services are not proprietary; rather such services can be, and in some circumstances are, provided by other vendors. Even though the license is useless without the R&D services and the customer is contractually restricted from reselling the technology, the fact that other vendors provide such R&D services is an indication that the license might have stand-alone value. This is because the vendor can license the technology separately while another vendor provides the on-going R&D services.
In summary, the analysis of stand-alone value must be based on the individual facts and circumstances for each arrangement.”
We also considered position papers by Ernst & Young, KPMG and PwC that support the determination of standalone value in the absence of the item being sold separately or the customer not having the ability to sell the item on a standalone basis. For the Staff’s convenience, we have attached the relevant extracts as Attachment
A to this response letter: Ernst & Young’s Technical Line of April 2, 2010 – Effects of New Multiple Element Revenue Guidance on Life Sciences R&D Collaborations; KPMG’s Accounting for Revenue Arrangements with
Multiple Deliverable of November 2010; and PWC’s Dataline whitepaper of January 2011.
Based on our interpretation of the aforementioned
SEC Staff speech and the accounting firms’ publication, we determined that, even though a customer may be precluded from reselling the license, a customer’s ability to use the delivered item for its intended purpose without the receipt of the remaining deliverables may indicate that the item has standalone value. The SEC Staff speech indicates that the customer is able to obtain the value intended from the delivered item and the customer could have purchased the delivered item on a standalone basis. We also considered that the absence of a secondary market does not preclude this license from having standalone value. We believe that upon delivery of the license to the collaborators, ViroPharma and Intrexon were each in a position to be able to use the delivered license for its intended purpose and could move their respective programs forward utilizing expertise and resources from either other vendors or their own internal capabilities, without us delivering the remaining deliverables included in the agreements.
R&D Services Standalone Value
ViroPharma is an international, publicly-traded biopharmaceutical company with 247 employees. ViroPharma has two marketed products, Cinryze® (C1 esterase inhibitor [human]) and Vancocin® and a robust pipeline with one product candidate under approval review, three product candidates in phase 2 clinical trials and one product candidate in preclinical stage of development.
Intrexon, founded in 1998, is a privately held synthetic biology company with over 400 patents and patent applications.
Intrexon employs over 200 employees with facilities in Maryland, Virginia, North Carolina and California.
The proprietary technology licensed by us to ViroPharma and Intrexon included in the license agreements relates primarily to our proprietary rHuPH20 enzyme. rHuPH20 enzyme can be applied to existing and developmental products of biopharmaceutical companies that market drugs requiring or benefiting from injection via subcutaneous route of administration. rHuPH20 is used as an active ingredient/excipient for enhancing the dispersion and/or absorption of the collaborators’ product or product candidate. The ViroPharma license agreement provides
ViroPharma the right to use our rHuPH20 technology in the development of a subcutaneous injectable formulation of ViroPharma’s existing product, Cinryze. The Intrexon license agreement provides Intrexon the right to use our rHuPH20 technology in the development of a subcutaneous injectable formulation of Intrexon’s licensed product candidates.
Pursuant to the terms of the ViroPharma and Intrexon agreements, ViroPharma and Intrexon are solely responsible for conducting development, manufacture, regulatory approval and commercialization of their respective licensed product candidates on their own. At the collaborators’ request, we will provide R&D services to the collaborators and are reimbursed at contractually determined rates. Although ViroPharma and Intrexon are solely responsible for conducting the development of their respective licensed product candidates, we believe they will use Halozyme to a certain extent for some of the R&D services. Accordingly, we have considered the delivery of the R&D services as a deliverable within the arrangement. As rHuPH20 is used as an active ingredient with the collaborators’ products and/or product candidates, the R&D services to be delivered by us mainly consist of development and regulatory services with respect to the rHuPH20 component of the product candidates. We determined that R&D services are not proprietary to us based on the facts that:
As rHuPH20 enzyme and hyaluron protein have been well characterized in life sciences, other vendors can provide similar R&D services as we have contracted with third parties to perform similar types of services in the past, and
Based on our observations during due diligence, we believe that ViroPharma and Intrexon each has the expertise and internal capabilities to perform such R&D services.
Once these entities have the rights to use the rHuPH20 technology, we believe ViroPharma and
Intrexon each can utilize resources from either other vendors or their own internal capabilities to move their respective programs forward without us providing R&D services. In addition, both ViroPharma and Intrexon have the right under the terms of the license agreements to transfer know-how to a third party solely for the purpose of developing, manufacturing or commercializing the licensed product candidates. As such, utilizing Halozyme’s R&D services is not necessary in order for ViroPharma and Intrexon to be able to obtain the value intended from the licenses.
rHuPH20 API Supply Standalone Value
Pursuant to the terms of the ViroPharma and Intrexon agreements, we will provide rHuPH20 API to the collaborators at their request and are reimbursed at our cost plus a margin. Although Viropharma and Intrexon are solely responsible for the manufacture of their respective licensed product candidates, as rHuPH20 is used as an active ingredient with their respective licensed products and/or product candidates, we believe they will purchase rHuPH20 API from us. As such, we consider the delivery of rHuPH20 API as a deliverable within the ViroPharma and Intrexon arrangements.
Management believes the rHuPH20 API supply has standalone value because the manufacturing process can be provided by other vendors. In fact, we have outsourced all of our manufacturing activities to third-party contract manufacturing organizations and plan to continue to do so. In addition, the agreements with ViroPharma and Intrexon include provisions that, in the event that we fail to deliver certain amount of rHuPH20 API as required by ViroPharma and Intrexon, allow
ViroPharma and Intrexon to contract directly with the contract manufacturing organizations for their rHuPH20 API supplies. As such, we determined that rHuPH20 API supply from Halozyme is not necessary in order for ViroPharma and Intrexon to be able to obtain the value intended from the license.
You state “the amount of allocable arrangement consideration is limited to amounts that are fixed or determinable; therefore, the amount allocated to the license was only to the extent of cash received.” Please tell us how your policy complies with ASC 605-25-30-5 which states that the amount allocable to the delivered item or items is the lesser of the amount otherwise allocable in accordance with paragraphs 605-25-30-2 and 30-4, or the noncontingent amount.
Response:
Pursuant to the terms of the ViroPharma license agreement, at the inception of the arrangement we received a nonrefundable upfront license fee payment of
$9 million and are entitled to receive payments upon achievement of certain development and regulatory milestones; annual exclusivity fees as long as the agreement is in effect; royalties on product sales and payments for R&D services and supply of rHuPH20 API if requested by ViroPharma.
Pursuant to the terms of the Intrexon license agreement, at the inception of the arrangement we received a nonrefundable upfront license fee payment of $9 million and are entitled to receive payments upon achievement of certain development and regulatory milestones and a sales-based milestone; annual exclusivity fees as long as the agreement is in effect; royalties on product sales and payments for R&D services and supply of rHuPH20 API if requested by Intrexon.
We determined that, in accordance with ASC 605-25, the license, R&D services and rHuPH20 API supply individually represent separate units of accounting. The guidance in ASC 605-25-30 requires that the arrangement consideration be allocated at the inception of the arrangement to all deliverables using the relative selling price method. ASC 605-25-30-5 states that the amount allocable to the delivered item or items is limited to the amount that is not contingent upon the delivery of additional items or meeting other specified performance conditions. That is, the amount allocable to the delivered item or items is the lesser of the amount otherwise allocable in accordance with paragraphs 605-25-30-2 and 30-4, or the noncontingent amount. As such, we excluded from the allocable arrangement consideration contingent payments regardless of the probability of receipt. We determined that the milestone, annual exclusivity fees and royalty payments are contingent and thus not considered fixed or determinable at the inception of the arrangements; therefore, such payments are excluded from the allocable arrangement consideration. Such payments will be evaluated separately as the related contingencies are resolved.
The license and all related know-how were delivered to ViroPharma and Intrexon following the execution of each agreement. We determined that the relative selling price of the license under the ViroPharma and Intrexon arrangements were far in excess of the upfront license fee of $9 million; however, we had received only the nonrefundable and noncontingent upfront license fee of $9 million each under the ViroPharma and Intrexon agreements at the inception of the arrangements. Therefore, we concluded that at the inception of the arrangements, the amount of arrangement consideration allocable to the delivered item, the license, is limited to the $9 million in nonrefundable upfront license fee payment we received each under the ViroPharma and Intrexon arrangements for the quarter ended June 30, 2011. Because the best estimated selling price of the license was significantly higher than the $9 million upfront license fee and the R&D services and API supply will be paid at amounts which approximate our best estimate of their selling prices, any relative selling price allocation would result in the $9 million upfront license fee being allocated to the license in the ViroPharma and Intrexon arrangements. As future payments become fixed or determinable, we will reassess the total arrangement consideration and the amount allocable to each deliverable accordingly.
Please provide us proposed disclosures to be included in future periodic reports of the total arrangement consideration and indicate the amount allocated to each deliverable, and;
Response:
In our future filings, beginning with our Form 10-Q for the quarter ending September 30, 2012, we will revise our disclosure in Note 3, Collaborative Agreements – ViroPharma and Intrexon
Partnerships as shown below (new text underlined and deleted text struck). The proposed disclosures are prepared as of March 31, 2012, the end of our first fiscal quarter, but will be revised in the Form 10-Q for the quarter ending
September 30, 2012 to reflect financial information as of September 30, 2012.
“Notes to Condensed
Consolidated Financial Statements
3. Collaborative Agreements
Effective May 10, 2011, we and ViroPharma entered into a collaboration and license agreement, under which ViroPharma obtained a worldwide exclusive license for the use of rHuPH20 enzyme in the development of a subcutaneous injectable formulation of ViroPharma’s commercialized product, Cinryze® (C1 esterase inhibitor [human]) (the “ViroPharma Partnership”). In addition, the license provides ViroPharma with exclusivity to C1 esterase inhibitor and to the hereditary angioedema indication, along with three additional orphan indications. As of March 31, 2012, we have received $12 million from ViroPharma, including the $9 million nonrefundable upfront license fee payment and a $3 million clinical development milestone payment. If ViroPharma successfully develops the licensed product candidate, we could receive additional milestone payments of up to $41 million for the achievement of development and regulatory milestones. In addition, so long as the agreement is in effect, we are entitled to receive a nonrefundable annual exclusivity fee of $1 million commencing on May 10, 2012 and on each anniversary of the effective date of the agreement thereafter until a certain development event occurs. ViroPharma is solely responsible for the development, manufacturing and marketing of any products resulting from this partnership. We are entitled to receive payments for research and development services and supply of rHuPH20 API if requested by ViroPharma. In addition, we are entitled to receive additional cash payments potentially totaling $10 million upon achievement of certain development and regulatory milestones for each product targeting the treatment of any of the three additional orphan indications. We are also entitled to receive royalties on future product sales by ViroPharmaa royalty on each product commercialized under the agreement consisting of ten percent of the net sales of such product. Unless terminated earlier in accordance with its terms, the
ViroPharma Partnership continues in effect until the later of (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the ViroPharma Partnership, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) ten years following the date of the first commercial sale of such product in such country. ViroPharma may terminate the agreement prior to expiration for any reason on a product-by-product basis upon 90 days prior written notice to us. Upon any such termination, the license granted to ViroPharma (in total or with respect to the terminated product, as applicable) will terminate.
Effective June 6, 2011, we and Intrexon entered into a collaboration and license agreement, under which Intrexon obtained a worldwide exclusive license for the use of rHuPH20 enzyme in the development of a subcutaneous injectable formulation of Intrexon’s recombinant human alpha 1-antitrypsin (rHuA1AT) (the “Intrexon Partnership”). In addition, the license provides Intrexon with exclusivity for a defined indication (“Exclusive
Field”). As of March 31, 2012, we have received a nonrefundable upfront license fee payment of $9 million from Intrexon. If Intrexon successfully develops the licensed product candidate and achieves the pre-agreed sales target, we could receive additional milestone payments of up to $54 million, including $44 million for the achievement of development and regulatory milestones and $10 million for the achievement of a sales-based milestone. In addition, so long as the agreement is in effect, we are entitled to receive a nonrefundable annual exclusivity fee of $1 million commencing on June 6, 2012 and on each anniversary of the effective date of the agreement thereafter until a certain development event occurs. Intrexon is solely responsible for the development, manufacturing and marketing of any products resulting from this partnership. We are entitled to receive payments for research and development services and supply of rHuPH20 API if requested by Intrexon. In addition, we are entitled to receive additional cash payments potentially totaling $10 million for each product for use outside the Exclusive Field upon achievement of development and regulatory milestones. We are also entitled to receive royaltiesa royalty on each product sales at a royalty rate which increases with net sales of productcommercialized under the agreement consisting of a percentage of the net sales of such product ranging from mid-single digits up to low double-digit percent. Unless terminated earlier in accordance with its terms, the Intrexon Partnership continues in effect until the later of (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the Intrexon Partnership, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) ten years following the date of the first commercial sale of such product in such country. Intrexon may terminate the agreement prior to expiration for any reason on a product-by-product basis upon 90 days prior written notice to us. Upon any such termination, the license granted to Intrexon (in total or with respect to the terminated product, as applicable) will terminate. Intrexon’s chief executive officer, chairman of its board of directors and major shareholder is also a member of our board of directors.
We identified the deliverables at the inception of the ViroPharma and Intrexon agreements which are the license, research and development services and API supply. We have determined that the license, research and development services and API supply individually represent separate units of accounting, because each deliverable has standalone value. The estimated selling prices for these units of accounting was determined based on market conditions, the terms of comparable collaborative arrangements for similar technology in the pharmaceutical and biotech industry and entity-specific factors such as the terms of our previous collaborative agreements, our pricing practices and pricing objectives and the nature of the research and development services to be performed for the partners. The arrangement consideration was allocated to the deliverables based on the relative selling price method.
other than for the potential effects of refund rights, concessions or performance bonuses. As such, we excluded from such allocable consideration the milestone payments, annual exclusivity fees and royalties regardless of the probability of receipt because such payments are not considered fixed or determinable. Such payments will be evaluated separately as the related contingencies are resolved. Based on the results of our analysis, we allocated the $9 million upfront license fee to the license deliverable under the ViroPharma arrangement and the $9 million upfront license fee to the license deliverable under the Intrexon arrangement. We determined that the upfront payment was earned upon the granting of the worldwide, exclusive right to our technology to the collaborator in both the ViroPharma Partnership and Intrexon Partnership. However, the amount of allocable arrangement consideration is limited to amounts that are fixed or determinable; therefore, the amount allocated to the license was only to the extent of cash received. As a result, we recognized the $9 million upfront license fee received under the ViroPharma Partnership and the $9 million upfront license fee received under the
Intrexon Partnership as revenues under collaborative agreements upon receipt of the upfront license fees.
We will recognize the annual exclusivity fees as revenues under collaborative agreements when they are earneddue and payable on each anniversary of the effective date and such amounts will be included in the allocable arrangement consideration and recognized based on the relative selling price allocation. We will recognize reimbursements foramounts allocated to research and development services as revenues under collaborative agreements as the related services are performed. We will recognize revenue fromamounts allocated to the sales of API as revenues under collaborative agreements when such API has met all required specifications by the partners and the related title and risk of loss and damages have passed to the partners. We cannot predict the timing of delivery of research and development services and API as they are at the partners’ requests.
We are eligible to receive additional cash payments upon the achievement by the partners of specified development, regulatory and sales-based milestones. We have determined that each of the development and regulatory milestones is substantive; therefore, we expect to recognize such development and regulatory milestone payments as revenues under collaborative agreements upon achievement in accordance with the Milestone Method. In addition, we have determined that the sales-based milestone payment is similar to a royalty payment and is not considered a milestone payment under the Milestone
Method of revenue recognition; therefore, we will recognize the sales-based milestone payment as revenue upon achievement of the milestone because we have no future performance obligations associated with the milestone. There were no milestone payments recognized as revenue under the collaborative agreements under these partnerships for the three months ended March 31, 2012 and 2011.”
Provide us an analysis of how you determined the total arrangement consideration and the amount allocated to each deliverable.
Response:
Pursuant to the guidance in ASC 605-25-30, we allocated the arrangement consideration at the inception of the arrangement to all deliverables on the basis of their relative selling price. ASU 2009-13 provides the hierarchy for estimating selling price as follows:
Vendor-specific objective evidence (“VSOE”) or the price at which the vendor regularly sells the item on a standalone basis,
If VSOE does not exist, the third-party evidence (“TPE”) of selling price must be used, or
If neither VSOE nor TPE exist, the vendor uses its best estimate of the selling price, which is the price at which the vendor would transact if the deliverable were sold regularly on a standalone basis.
The VSOE and TPE do not exist due to the uniqueness of our license. Nor are there other vendors that sell similar technology. Therefore, we used our best estimate of the selling price in the allocation of the ViroPharma and Intrexon arrangement consideration. The best estimated selling price for the units of accounting within the ViroPharma and Intrexon arrangements were determined based on market conditions, the terms of comparable collaborative arrangements for similar technology in the pharmaceutical and biotech industry and entity-specific factors such as the terms of our previous collaborative agreements, our pricing practices and pricing objectives and the nature of R&D services to be performed by the collaborators. We estimated the selling price of the license under the ViroPharma and Intrexon agreements utilizing a discounted net present value model. The model was developed as part of our due diligence to help determine the estimated value of the arrangement. We determined that the estimated selling prices of the respective licenses in the ViroPharma and Intrexon arrangements were individually far in excess of the upfront license fees that we received under each arrangement.
R&D services to be provided by us to the collaborators will be reimbursed by ViroPharma and Intrexon based on the labor rate that was agreed upon which was based on typical rates charged for similar services in the biotech industry. We used our best estimate of selling price after considering TPE of selling price, and concluded that the agreed-upon labor rate represents the best estimated selling price of R&D services. Because the best estimated selling price of the license was significantly higher than the $9 million upfront license fee and the R&D services will be paid at amounts which approximate our best estimate of their selling prices, any relative selling price allocation would result in the $9 million upfront license fee being allocated to the license.
Supply of rHuPH20 API to be provided by us to the collaborators are at the request of the collaborators and are being paid by ViroPharma and Intrexon at our cost plus a certain margin that was agreed upon which was not inconsistent with biotech contract manufacturing arrangements. We also took into consideration what we had charged other collaborators in the past for similar supply services to further support the estimated selling price. We concluded that the rate of our cost plus the agreed-upon margin represents the best estimated selling price of the API supply. Because the best estimated selling price of the license was significantly higher than the $9 million upfront license fee and the API supply will be paid at amounts which approximate our best estimate of their selling prices, any relative selling price allocation would result in the $9 million upfront license fee being allocated to the license.
ASC 605-25-30-5 states that the amount allocable to the delivered item or items is limited to the amount that is not contingent upon the delivery of additional items or meeting other specified performance conditions. That is, the amount allocable to the delivered item or items is the lesser of the amount otherwise allocable in accordance with paragraphs 605-25-30-2 and 30-4, or the noncontingent amount. At the inception of the arrangements, we have received only the nonrefundable, noncontingent upfront license fees; therefore, we concluded that at the inception of the arrangements, the amount of arrangement consideration allocable to the delivered item, the license, is limited to the $9 million upfront license fee payment we received each under the ViroPharma and Intrexon arrangements for the quarter ended June 30, 2011. Because the best estimated selling price of the license was significantly higher than the $9 million upfront license fee and the R&D services and API supply will be paid at amounts which approximate our best estimate of their selling prices, any relative selling price allocation would result in the
$9 million upfront license fee being allocated to the license in the ViroPharma and Intrexon arrangements.
The milestone, annual exclusivity fee and royalty payments are contingent payments and not considered fixed or determinable at the inception of the arrangements; therefore, such payments are excluded from the allocable arrangement consideration. Contingent amounts will be evaluated separately as the related contingencies are resolved. We will also continue to evaluate the consideration for R&D services and supply of rHuPH20 API as these services are requested to be provided by us to ViroPharma and Intrexon. To the extent of materiality, we will reassess the allocable arrangement consideration and reallocate to the units of accounting in the arrangements accordingly.
Item 2.